- Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletion
- Longer-term data from a pooled analysis from the ALLCAR19 study and FELIX Phase Ib in r/r B-ALL showed durable remissions with obe-cel as a stand-alone therapy in a subset of patients after a median follow up of >3 years
- Additionally, ALLCAR19 extension cohorts demonstrated long-term responses with low immunotoxicity and prolonged persistence in patients with aggressive and indolent r/r NHL and r/r CLL
- Initial data from the MCARTY Phase I study in multiple myeloma showed AUTO8 was well tolerated, with responses observed in all patients
Autolus will host an in-person and webcast Analyst/Investor event to discuss the data onSunday, December 10, 2023 at8:00 AM PT /4.00 PM GMT
Webcast Registration: A live webcast will be held alongside the event. To register for the webcast please follow this link.
A recording of the event together with the presentation materials will be available on the Company’s website after the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.